FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 240 filers reported holding FATE THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.68 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $2,795,404 | -41.5% | 277,047 | +30.0% | 0.05% | -57.9% |
| Q3 2022 | $4,777,000 | +128.6% | 213,168 | +295.5% | 0.13% | +37.0% |
| Q1 2022 | $2,090,000 | +2.5% | 53,897 | +56.6% | 0.09% | -36.1% |
| Q3 2021 | $2,040,000 | +61.4% | 34,427 | +136.4% | 0.14% | -5.9% |
| Q2 2021 | $1,264,000 | +104.5% | 14,566 | +94.2% | 0.15% | +70.0% |
| Q1 2021 | $618,000 | – | 7,500 | – | 0.09% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Polaris Venture Management Co. V, L.L.C. | 569,889 | $46,987,000 | 60.92% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,379,064 | $278,604,000 | 36.08% |
| Darwin Global Management, Ltd. | 1,370,133 | $112,967,000 | 22.12% |
| Redmile Group, LLC | 12,957,222 | $1,068,323,000 | 15.05% |
| Copernicus Capital Management, LLC | 8,000 | $660,000 | 10.66% |
| Casdin Capital, LLC | 3,400,000 | $280,330,000 | 8.35% |
| Grosvenor Holdings, L.L.C. | 1,123,576 | $92,639,000 | 6.81% |
| DAFNA Capital Management LLC | 314,360 | $25,919,000 | 6.15% |
| Ally Bridge Group (NY) LLC | 270,000 | $22,262,000 | 4.27% |
| Ghost Tree Capital, LLC | 185,000 | $15,253,000 | 3.58% |